Perceive Biotherapeutics is a clinical stage company developing novel drugs and gene therapies for ocular diseases.

Perceive’s lead program for age-related macular degeneration (AMD) is a gene therapy delivering an engineered, protective complement factor transgene to genetically defined patients at risk of developing both dry and wet AMD. Perceive’s second program is a neuroprotective gene therapy aimed at slowing vision loss in a variety of disease instances, with the primary indication being glaucoma. Catalio Venture Partner Eugene De Juan is the company’s CSO.